Skip to main content
. 2021 Jul 16;30:09636897211033778. doi: 10.1177/09636897211033778

Figure 4.

Figure 4.

SHR0302 increased Tregs and reduced Th1 cells. (A) The cell counts of bone marrow (BM) and spleen in 4 group mice: vehicle-6Ws, SHR0302-16Ws, TCD-BMT-6Ws, and healthy recipient control (n = 9 for each group) (6Ws and 16Ws: at 6th and 16th weeks after transplantation, respectively). (B) The percentages of CD3+ T cells and CD19+ B cells in spleen cells in four groups: vehicle-6Ws (n = 10), SHR0302-16Ws (n = 11), TCD-BMT-6Ws (n = 9), and healthy recipient control (n = 9). (C) The percentages of CD4+ T cells and CD8+ T cells in all T cells of spleen in four groups: vehicle-6Ws (n = 10), SHR0302-16Ws (n = 11), TCD-BMT-6Ws (n = 9), and healthy recipient control group (n = 9). (D) The percentages of CD4+Foxp3+ cells of spleen in vehicle-6Ws (n = 7), SHR0302-16Ws (n = 11), TCD-BMT-6Ws (n = 9), and healthy recipient control groups (n = 9), respectively. (E) The percentages of CD4+IFN-γ+ cells in all CD4+ cells of spleen in four groups: vehicle-6Ws (n = 5), SHR0302-16Ws (n = 5), TCD-BMT-6Ws (n = 3), and healthy recipient control (n = 3). (F) The percentages of CD8+IFN-γ+ cells in all CD8+ cells of spleen in four groups: vehicle-6Ws (n = 5), SHR0302-16Ws (n = 5), TCD-BMT-6Ws (n = 3), and healthy recipient control mice (n = 3). Data were pooled from two separate experiments in Figure A-D. Bars show the mean ± SEM. *P < 0.05.